Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 9;5(2):e000605. doi: 10.1136/esmoopen-2019-000605

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Forest plots of survival comparison in patients with right-sided metastatic colorectal cancer receiving first-line chemotherapy or chemotherapy plus targeted mAbs. (A) Chemotherapy (CT) vs chemotherapy plus bevacizumab (CT+Bev) in the right-sided patients. (B) Adjuvant chemotherapy plus bevacizumab (CT+Bev) vs adjuvant chemotherapy plus anti-EGFR antibody (CT+anti EGFR) in RAS-wild right-sided patients. EGFR, epithelial growth factor receptor; mAbs, monoclonal antibodies; MSR, median survival ratio; OS, overall survival; PFS, progression-free survival.